Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia
- PMID: 17701167
- DOI: 10.1007/s00228-007-0345-x
Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia
Abstract
Objective: The aim of this study was to assess the effect of treatment with a St. John's wort product (Movina) on cholesterol [total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol] and triglyceride levels in patients with hypercholesterolemia on treatment with a stable dose of atorvastatin in a controlled, randomised, open, crossover interaction study.
Methods: Sixteen patients with hypercholesterolemia treated with a stable dose of atorvastatin (10-40 mg/daily) for at least 3 months were treated with Movina one tablet (containing 300 mg of hypericum perforatum) twice daily and control (a commercially available multivitamin tablet Vitamineral). After a run-in period of 4 weeks, patients were randomised to treatment with either Movina or control for 4 weeks in a crossover design. The atorvastatin dose was kept unchanged during the study period (12 weeks), and assessments of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were performed in the morning with the patients in the fasting condition. The difference between control and active treatment in LDL cholesterol after 4 weeks of treatment was the primary endpoint.
Results: All patients completed the study. The St. John's wort product significantly increased the serum level of LDL cholesterol compared with control (2.66 mmol/l compared with 2.34 mmol/l, p = 0.004). A significant increase in total cholesterol was also observed (5,10 mmol/l compared with 4.78 mmol/l, p = 0.02). No statistically significant change was observed in HDL cholesterol (1.59 mmol/l and 1.56 mmol/l, p = 0.49) or in triglycerides (1.87 mmol/l and 1.94 mmol/l, p = 0.60). No product-related side effects were reported
Conclusion: An interaction was observed between the studied St.-John's-wort-containing product and atorvastatin. Physicians and patients should be aware of this interaction and if treatment with a St. John's wort product is considered necessary, then there may be a need for increasing the dose of atorvastatin.
Comment in
-
What is the true risk of a pharmacokinetic drug-drug interaction?Eur J Clin Pharmacol. 2007 Oct;63(10):897-9. doi: 10.1007/s00228-007-0357-6. Eur J Clin Pharmacol. 2007. PMID: 17684737 No abstract available.
Similar articles
-
Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin.Scand J Prim Health Care. 2007 Sep;25(3):154-9. doi: 10.1080/02813430701442768. Scand J Prim Health Care. 2007. PMID: 17846933 Free PMC article. Clinical Trial.
-
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.Clin Pharmacol Ther. 2000 Dec;68(6):598-604. doi: 10.1067/mcp.2000.112240. Clin Pharmacol Ther. 2000. PMID: 11180019
-
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.Clin Ther. 2007 Nov;29(11):2365-73. doi: 10.1016/j.clinthera.2007.11.002. Clin Ther. 2007. PMID: 18158077 Clinical Trial.
-
Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond!Nephrology (Carlton). 2008 Jun;13(4):337-47. doi: 10.1111/j.1440-1797.2008.00940.x. Epub 2008 Mar 17. Nephrology (Carlton). 2008. PMID: 18363644 Review.
-
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.Drugs. 2001;61(12):1835-81. doi: 10.2165/00003495-200161120-00012. Drugs. 2001. PMID: 11693468 Review.
Cited by
-
Curdione Plays an Important Role in the Inhibitory Effect of Curcuma aromatica on CYP3A4 in Caco-2 Cells.Evid Based Complement Alternat Med. 2011;2011:913898. doi: 10.1093/ecam/nep229. Epub 2011 Mar 13. Evid Based Complement Alternat Med. 2011. PMID: 21785639 Free PMC article.
-
Critical evaluation of causality assessment of herb-drug interactions in patients.Br J Clin Pharmacol. 2018 Apr;84(4):679-693. doi: 10.1111/bcp.13490. Epub 2018 Jan 29. Br J Clin Pharmacol. 2018. PMID: 29363155 Free PMC article. Review.
-
Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.AAPS J. 2009 Dec;11(4):710-27. doi: 10.1208/s12248-009-9146-8. Epub 2009 Oct 27. AAPS J. 2009. PMID: 19859815 Free PMC article. Review.
-
Documentary Analysis of Hypericum perforatum (St. John's Wort) and Its Effect on Depressive Disorders.Pharmaceuticals (Basel). 2024 Dec 3;17(12):1625. doi: 10.3390/ph17121625. Pharmaceuticals (Basel). 2024. PMID: 39770466 Free PMC article. Review.
-
Hypericum perforatum: Traditional uses, clinical trials, and drug interactions.Iran J Basic Med Sci. 2022 Sep;25(9):1045-1058. doi: 10.22038/IJBMS.2022.65112.14338. Iran J Basic Med Sci. 2022. PMID: 36246064 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical